硫普罗宁治疗抗痨药物性肝炎33例

目的 探讨硫普罗宁对抗痨药物性肝炎的临床疗效.方法 抗痨药物性肝炎66例,随机分成二组,对照组33例常规护肝治疗,治疗组33例加用硫普罗宁注射液0.2,iv drop qd,4周一疗程.结果 治疗组在临床症状消失时间及治疗效果方面显优于对照组,(P＜0.05).结论 硫普罗宁治疗抗痨药物性肝炎有较好疗效.     

硫普罗宁的临床应用研究

目的探讨硫普罗宁的临床应用效果。方法 45例给予硫普罗宁药物进行治疗的患者,随机分为实验组(25例)和对照组(20例),实验组采用硫普罗宁注射液,对照组采用肌内注射硫普罗宁药物,观察两组患者的临床治疗效果。结果实验组患者的治疗总有效率、不良反应的发生率及各项肝功能指标优于对照组,差异有统计学意义(P<0.05)。结论硫普罗宁对于治疗肝病的效果显著,采用静脉滴注的效果优于肌内注射,不良反应的发生率低,值得临床推广。     

硫普罗宁在恶性肿瘤治疗中的临床应用及进展

目的介绍硫普罗宁在恶性肿瘤治疗中的临床应用及进展。方法检索近年来国内外有关硫普罗宁药理作用、临床应用及进展的文献资料,加以整理、归纳。结果硫普罗宁作为新型的的含巯基甘氨酸药物,具有促肝细胞再生、清除自由基、调节免疫和解毒等药理作用。结论硫普罗宁在恶性肿瘤化疗方案中虽为辅助药物,却发挥着预防肝损伤、保护肝功能、防治粒细胞减少、增效减毒及杀伤肿瘤细胞、诱导其凋亡等重要作用。     

脂必泰联合硫普罗宁与阿托伐他汀联合硫普罗宁治疗非酒精性脂肪肝的疗效比较

目的 比较脂必泰联合硫普罗宁与阿托伐他汀联合硫普罗宁治疗非酒精性脂肪肝的疗效.方法 80例非酒精性脂肪肝病患者,随机分为脂必泰联合硫普罗宁组和阿托伐他汀联合硫普罗宁组,疗程8周.观察比较两治疗前后肝功能及临床疗效.结果 治疗8周后,治疗组显效33例、有效3例、无效0例、总有效率90.0％,对照组分别为32例、3例、5例、87.5％,两组总有效率差异无统计学意义(P＞0.05).两组治疗后肝功能较治疗前明显改善(t =751.130、19.710、19.835、279.093,均P＜0.05);两组治疗后血脂均较治疗前明显改善(t=24.174、738.588、140.730、506.385,均P＜0.05),两组治疗后血脂水平差异均无统计学意义(均P＞0.05).结论 脂必泰联合硫普罗宁与阿托伐他汀联合硫普罗宁治疗非酒精性脂肪肝均安全有效.     

注射用硫普罗宁钠与与注射用硫普罗宁的比较分析

通过比较注射用硫普罗宁钠与注射用硫普罗宁生产工艺、性质、安全性等的比较分析。注射用硫普罗宁钠的上市为广大肝病患者提供了新的治疗药物,其质量可控、疗效确切、临床安全、使用方便,为广大急、慢性肝病患者带来福音,市场应用前景广阔,将产生良好的社会效益和经济效益。     

硫普罗宁纳在临床中的应用进展初探

目的：探究硫普罗宁纳在临床中的应用进展。方法对国内外近几年关于硫普罗宁纳的药理作用、药动学、临床应用以及不良反应等文献进行分析、整理和归纳。结果硫普罗宁纳作为一种新型的含巯基甘氨酸药物,具有促进肝细胞再生、对重金属解毒以及清除自由基等的药理作用。结论硫普罗宁纳不仅可以用于治疗急性和慢性肝炎、酒精性和非酒精性脂肪肝、肝硬化以及药物肝损伤,同时还可以用来腹部手术后胃黏膜损伤的保护,以及肝肿瘤围术期肝脏功能的保护。     

注射用硫普罗宁治疗慢性乙型肝炎疗效观察

目的　观察注射用硫普罗宁治疗慢性乙型肝炎的临床疗效。方法　 30例慢性乙型肝炎患者随机分为治疗组 2 0例和对照组 1 0例。治疗组以注射用硫普罗宁治疗 ,对照组采用肝炎灵注射液治疗 ,2组疗程均为 3周。结果　 2组患者的临床症状 ,肝功能都有明显改善 ,但治疗组疗效明显优于对照组 (P <0 .0 5 ) ,总有效率为95 % ,且均未发现明显不良反应。结论　注射用硫普罗宁治疗慢性乙型肝炎有良好的改善临床症状和肝功能指标的作用 ,安全有效     

硫普罗宁致肾病综合征的报告分析

目的:探讨硫普罗宁导致肾病综合征的特点及治疗,为临床安全用药提供参考.方法:经查阅相关文献,对硫普罗宁引起肾病综合征患者的临床病理特点、治疗预后等进行总结,并对我院收治的2名因使用硫普罗宁导致肾病综合征患者的实际情况进行分析.结果:文献报道29例硫普罗宁引起的肾病综合征病例,其中,男性16倒,女性13例;年龄最小20个月,最大73岁;用药1月～2年的患者有14例;9例行肾活检,以膜性肾病为主(6例);29例患者中给予激素治疗者3例,免疫抑制剂治疗者1例,其他给予对症支持治疗者25例,所有患者均恢复正常,完全恢复时间小于5周.我科收治2例患者,男女各1名,年龄分别为76岁和62岁,院外抗结核常规给予硫普罗宁保肝治疗,分别在用药9、11周后出现大量蛋白尿、低蛋白血症,临床诊断肾病综合征;1例肾活检病理诊断肾小球微小病变,未给予激素及免疫抑制剂治疗,停用硫普罗宁后1～2个月肾病自行缓解.结论:硫普罗宁长期应用可以导致肾病综合征,病理类型表现多样,多数停药后可自行缓解.建议长期使用该药的患者应注意肾脏损害,早期发现及时停药,预后较好.     

硫普罗宁联合促肝细胞生成素治疗药物性肝损伤52例临床分析

目的研究硫普罗宁联合促肝细胞生成素治疗药物性肝损伤的临床疗效。方法 52例药物性肝损伤患者随机分为治疗组和对照组。结果治疗组治疗后,肝功能明显改善,且改善幅度明显高于对照组;治疗组早期应用硫普罗宁及促肝细胞生成素可以提高疗效、缩短病程。结论硫普罗宁联合促肝细胞生成素治疗药物性肝损伤疗效显著。     

硫普罗宁的临床应用及药理作用探讨

目的探究硫普罗宁的临床应用效果及药理作用,为临床提供指导。方法以来我院就医的70例慢性乙型肝炎患者(2015年5月11日至2016年12月20日)作为本次研究的观察对象,使用随机数字表法对70例慢性乙型肝炎患者进行分组。常规组35例患者应用常规治疗,硫普罗宁组35例患者在常规组患者的基础上应用硫普罗宁治疗,研究对比两组慢性乙型肝炎患者的临床疗效及肝功能变化情况。结果硫普罗宁组患者的总有效率为100.00%,相比常规组明显更高,P<0.05;硫普罗宁组患者治疗后的ALT、AST水平相比常规组明显更低,P<0.05。结论对慢性乙型肝炎患者采取硫普罗宁治疗切实可行,可有效改善患者的肝功能。     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.     

Gender-related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders

This study explored gender-related symptoms and correlates of alcohol dependence in a crosssectional study of 150 men and 150 women with a lifetime diagnosis of alcohol use disorders (AUD). Participants were recruited in equal numbers from treatment settings, correctional centres and the general community. Standardized measures were used to determine participants' use of substances, history of psychiatric disorders and psychosocial stress, their sensation seeking and family history of substance use and mental health disorders. Multivariate analyses were used to detect patterns of variables associated with gender and the lifetime severity of AUD. Men had a longer history of severe AUD than women. Women had similar levels of alcohol dependence and medical and psychological sequelae as men, despite 6 fewer years of AUD. More women than men had a history of severe psychosocial stress, severe dependence on other substances and antecedent mental health problems, especially mood and anxiety disorders. There were differences in family history of alcohol-related problems approximating same-gender aggregation. The severity of a lifetime AUD was predicted by its earlier age at onset and the occurrence of other disorders, especially anxiety, among both men and women. The limitations in the generalizability of these findings due to sample idiosyncrasies are discussed.     

Biochemical and molecular characterisation of cubozoan protein toxins

Class Cubozoa includes several species of box jellyfish that are harmful to humans. The venoms of box jellyfish are stored and discharged by nematocysts and contain a variety of bioactive proteins that are cytolytic, cytotoxic, inflammatory or lethal. Although cubozoan venoms generally share similar biological activities, the diverse range and severity of effects caused by different species indicate that their venoms vary in protein composition, activity and potency. To date, few individual venom proteins have been thoroughly characterised, however, accumulating evidence suggests that cubozoan jellyfish produce at least one group of homologous bioactive proteins that are labile, basic, haemolytic and similar in molecular mass (42-46 kDa). The novel box jellyfish toxins are also potentially lethal and the cause of cutaneous pain, inflammation and necrosis, similar to that observed in envenomed humans. Secondary structure analysis and remote protein homology predictions suggest that the box jellyfish toxins may act as α-pore-forming toxins. However, more research is required to elucidate their structures and investigate their mechanism(s) of action. The biological, biochemical and molecular characteristics of cubozoan venoms and their bioactive protein components are reviewed, with particular focus on cubozoan cytolysins and the newly emerging family of box jellyfish toxins.     

Dose tolerability of chronically inhaled voriconazole solution in rodents

Invasive pulmonary aspergillosis (IPA) is a fungal disease of the lung associated with high mortality rates in immunosuppressed patients despite treatment. Targeted drug delivery of aqueous voriconazole solutions has been shown in previous studies to produce high tissue and plasma drug concentrations as well as improved survival in a murine model of IPA. In the present study, rats were exposed to 20 min nebulizations of normal saline (control group) or aerosolized aqueous solutions of voriconazole at 15.625 mg (low dose group) or 31.25 mg (high dose group). Peak voriconazole concentrations in rat lung tissue and plasma after 3 days of twice daily dosing in the high dose group were 0.85 ± 0.63 μg/g wet lung weight and 0.58 ± 0.30 μg/mL, with low dose group lung and plasma concentrations of 0.38 ± 0.01 μg/g wet lung weight and 0.09 ± 0.06 μg/mL, respectively. Trough plasma concentrations were low but demonstrated some drug accumulation over 21 days of inhaled voriconazole administered twice daily. Following multiple inhaled doses, statistically significant but clinically irrelevant abnormalities in laboratory values were observed. Histopathology also revealed an increase in the number of alveolar macrophages but without inflammation or ulceration of the airway, interstitial changes, or edema. Inhaled voriconazole was well tolerated in a rat model of drug inhalation.